SCHEMBL16197051

SCHEMBL16197051

O=C1Nc2ccc(Br)cc2C1(O)c1ccc(F)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 4/20 0.54
LMNA P02545 2/20 0.47
POLB P06746 2/20 0.46
CASP6 P55212 1/20 0.46
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
ALDH1A1 P00352 1/20 0.44
PKM P14618 1/20 0.43
CYP3A4 P08684 1/20 0.42
CYP2C19 P33261 1/20 0.42
TP53 P04637 1/20 0.42
AKR1A1 P14550 1/20 0.42
AKR1B1 P15121 1/20 0.42
GAA P10253 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
PIM1 P11309 1/20 0.40
CCNB2 O95067 1/20 0.40
CDK1 P06493 1/20 0.40
CCNB1 P14635 1/20 0.40
CCNB3 Q8WWL7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16197245 0.85 BRD4 (0.52) BRD4LMNAPOLBCASP6MEN1
SCHEMBL24281860 0.79 HTT (0.56) BRD4LMNAPOLBCASP6MEN1
SCHEMBL24281278 0.78 POLB (0.65) BRD4LMNAPOLBCASP6MEN1
SCHEMBL28519633 0.77 KMT2A (0.40) LMNAPOLBMEN1KMT2AALDH1A1
SCHEMBL5472848 0.74 PIM1 (0.59) LMNAMEN1KMT2APKMCYP2C19
SCHEMBL27400418 0.74 BRD4 (0.48) BRD4LMNAPOLBCASP6MEN1
SCHEMBL31727514 0.73 BRD4 (0.40) BRD4LMNAPOLBCASP6KMT2A
SCHEMBL13284255 0.73 USP2 (0.67) MEN1KMT2AALDH1A1PKMTP53
SCHEMBL2499492 0.72 BRD4 (0.57) BRD4LMNAPOLBCASP6MEN1
SCHEMBL543298 0.72 PDK2 (0.44) MEN1KMT2AALDH1A1TP53AKR1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2989096-B1 SUBSTITUTED 5-(3,5-DIMETHYLISOXAZOL-4-YL)INDOLINE-2-ONES BEIGENE LTD (KY) 2019-04-10 EP disclosed
EP-2989096-B1 SUBSTITUTED 5-(3,5-DIMETHYLISOXAZOL-4-YL)INDOLINE-2-ONES BEIGENE LTD (KY) 2019-04-10 EP disclosed
US-9827226-B2 Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones BEIGENE, LTD. (KY) 2017-11-28 US disclosed
US-9827226-B2 Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones BEIGENE, LTD. (KY) 2017-11-28 US disclosed
US-9827226-B2 Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones BEIGENE, LTD. (KY) 2017-11-28 US disclosed
US-20170027912-A1 SUBSTITUTED 5-(3,5-DIMETHYLISOXAZOL-4-YL)INDOLINE-2-ONES BEONE MEDICINES I GMBH (CH) 2017-02-02 US disclosed
US-20170027912-A1 SUBSTITUTED 5-(3,5-DIMETHYLISOXAZOL-4-YL)INDOLINE-2-ONES BEONE MEDICINES I GMBH (CH) 2017-02-02 US disclosed
US-20170027912-A1 SUBSTITUTED 5-(3,5-DIMETHYLISOXAZOL-4-YL)INDOLINE-2-ONES BEONE MEDICINES I GMBH (CH) 2017-02-02 US disclosed
US-9393232-B2 Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones BEIGENE, LTD. (KY) 2016-07-19 US disclosed
US-9393232-B2 Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones BEIGENE, LTD. (KY) 2016-07-19 US disclosed
US-9393232-B2 Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones BEIGENE, LTD. (KY) 2016-07-19 US disclosed
EP-2989096-A1 SUBSTITUTED5-(3,5-DIMETHYLISOXAZOL-4-YL)INDOLINE-2-ONES BeiGene, Ltd. (KY) 2016-03-02 EP disclosed
US-20160030395-A1 SUBSTITUTED 5-(3,5-DIMETHYLISOXAZOL-4-YL)INDOLINE-2-ONES BEONE MEDICINES I GMBH (CH) 2016-02-04 US disclosed
US-20160030395-A1 SUBSTITUTED 5-(3,5-DIMETHYLISOXAZOL-4-YL)INDOLINE-2-ONES BEONE MEDICINES I GMBH (CH) 2016-02-04 US disclosed
US-20160030395-A1 SUBSTITUTED 5-(3,5-DIMETHYLISOXAZOL-4-YL)INDOLINE-2-ONES BEONE MEDICINES I GMBH (CH) 2016-02-04 US disclosed
WO-2014173241-A1 SUBSTITUTED5-(3,5-DIMETHYLISOXAZOL-4-YL)INDOLINE-2-ONES BEIGENE, LTD. (GB) 2014-10-30 WO disclosed
WO-2014173241-A1 SUBSTITUTED5-(3,5-DIMETHYLISOXAZOL-4-YL)INDOLINE-2-ONES BEIGENE, LTD. (GB) 2014-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170027912-A1 SUBSTITUTED 5-(3,5-DIMETHYLISOXAZOL-4-YL)INDOLINE-2-ONES BRD4, BRPF3, BRD3 BRD4 1/4885LMNA 1590/4885POLB 569/4885
US-20160030395-A1 SUBSTITUTED 5-(3,5-DIMETHYLISOXAZOL-4-YL)INDOLINE-2-ONES BRD4, BRPF3, BRD3 BRD4 1/4885LMNA 1590/4885POLB 569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.